The CRO focuses its services towards biotechs by stating that they are cheaper and more efficient compared to rivals, and it was this principle that drew in General Catalyst to provide investment.
ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseases.
First ever longtudinal study from ALS non-profit focuses on finding digital biomarkers using IBM Research’s proprietary AI. The study leverages audiovisual samples from participants with ALS, genetic carriers, and caregivers.
For its two lead oncology programs, the company will pursue “market-based pricing”, moving away from plans to “dramatically lower prices” for treatments.
The two companies will combine real-world datasets to better understand marketing treatment with Bristol Myers Squibb’s drug in a post-marketing setting.
Icon is looking to its Accellacare global clinical research network to mitigate the effect of site staffing issues on the speed at which trials are executed and revenues are realized.
In-home nurse visits, using familiar mobile devices to upload health data, and telemedicine calls with a doctor are the elements of decentralized clinical trials with the biggest positive impact on participation in future studies, according to a survey.
CVS Health and Walgreens announce that they will settle all opioid claims against them by US states, while it is reported that Walmart will do the same.
The long-running case relates to the change of formulation to its Levothyrox product, specifically the information the company provided when the product was altered.
CPhI Frankfurt takes place next week: covering the full supply chain from research and manufacturing to packaging and finished products. Here’s five ideas on how to make the most of the event.
A federal judge in the Southern District of Florida has sentenced two Florida women to prison for their part in a conspiracy to falsify clinical trial data.
According to the agency, Teva communicated that it would have difficulties supplying immediate release formulations of the drug due to manufacturing delays.
The regulatory agencies of six European countries are now actively prompting clinical trials sponsors to publicly report their clinical trial results—and have the power to issue fines of up to €250,000 ($243,000) for noncompliance.
The company announces further measures against a counterfeiting network it accused of being responsible for selling illegitimate Gilead HIV medications.
The company will commercialise the therapy in Europe, after having previously agreed the rights to treatment in Europe and Japan through a licensing deal with Aurinia.
Adding to broader action being taken across the industry, the company has signed an agreement with Enel for the supply of renewable energy credits covering its electricity needs across the US.
Thermo Fisher Scientific’s clinical service unit PPD has won some “very large” customers since becoming part of the broader group in a mega-merger, according to CEO Marc Casper.
Australian CRO Avance Clinical has expanded in North America by acquiring C3 Research Associates, positioning it to continue supporting sponsors as they move into later-phase studies that need US sites.
UK-based biopharmaceutical company, PhoreMost, is to deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche.
A collaboration between Touchlight and Lonza expands the Swiss CDMO’s end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material, the UK biotech’s doggybone DNA (dbDNA).
Bioprocessing 4.0 and digitalization is all about embracing new technologies to enable faster, smoother and more efficient biomanufacturing. And that also requires embracing a new mindset.
With the purchase, the company is looking to advance its plans to connect with potential trial participants and spread awareness of study participation.
This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.
The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.
The National Institutes of Health grant to AVM Biotechnology will be used to evaluate a drug to treat non-Hodgkin’s lymphoma combined with standard of care.
The pharmaceutical company and the artificial intelligence pathology specialist will focus on translational research in oncology, fibrosis, and immunology.
The group’s latest report glimpses inside the minds of pharma leaders, who are looking at a product’s full life-cycle development at the preclinical stage.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
The National Institute for Health and Care Excellence is weighing the viability of PD Neurotechnology’s PDMonitor system for Parkinson’s disease patients.
After scientists and reporters raised red flags about a study, Cassava Sciences is being accused of falsifying data in pursuit of an Alzheimer’s treatment.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
